Intervention

human soluble insulin

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 6 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials6
Recruiting0
Common conditions4
Lead sponsors shown1
Advertisement

Clinical trials

6 shown
Comparing Efficacy and Safety of Insulin Detemir Plus Insulin Aspart and NPH Insulin Plus Human Soluble Insulin With or Without Metformin in Chinese Patients With Type 2 DiabetesNCT01486966 · 2011-11-01
TERMINATED
Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and HyposNCT01542489 · 2006-10-01
COMPLETED
NovoLet® Surveillance Study on Using Human Insulin System in IndonesiaNCT01492153 · 2003-02-11
COMPLETED
Comparison of Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin in Subjects With Type 1 DiabetesNCT01486940 · 2002-03-01
COMPLETED
A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human InsulinNCT02162407 · 1999-10-01
COMPLETED
Safety and Efficacy of Insulin Aspart in Subjects With Type 1 DiabetesNCT01707134 · 1997-09-01
COMPLETED

Trial status mix

COMPLETED5
TERMINATED1

Phase mix

PHASE32
PHASE11
PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.